A Fundamental Look At The Investment Potential of Actinium Pharmaceuticals Inc.

Actinium Pharmaceuticals Inc.

  • Actinium Pharmaceuticals Inc. (NYSE:ATNM) is a clinical-stage biopharmaceutical company focused on developing and potentially commercializing targeted therapies for improved myeloablation (the decrease in bone marrow activity) and conditioning of the bone marrow prior to a bone marrow transplant and for the targeting and killing of cancer cells.

About the Leading Product, Iomab-B

  • Iomab-B was created with the goal of improving bone marrow transplant (BMT) access and outcomes for patients with blood cancers such as leukemia, lymphoma or multiple myeloma.
  • Iomab-B is intended to prepare and condition patients for a BMT which is often considered the only potential cure for patients with certain blood cancers.
  • The drug carries iodine-131 directly to the bone marrow in a targeted manner with the intent for patients to avoid the side effects of radiation while effectively killing the patient’s cancer and marrow cells.
  • Stage II clinical trials were a major success, as Iomab-B produced complete remissions in 100% of the 68 patients with advanced AML or high-risk myelodysplastic syndrome age 50 and older. All patients achieved full donor chimerism by day 28 post-transplant.
  • Currently showing promise during stage III clinical trials, and approval is likely due to the lack of viable alternatives.


  • Upon successful completion of the Phase 3 clinical trial for Iomab-B, Actinium intends to submit for marketing approval in the U.S. and European Union.
  • Iomab-B will be marketed to patients with relapsed or refractory acute myeloid leukemia who are age 55 and above.
  • According to the Journal of Medical Economics, the current cost for autologous and allogeneic BMTs ranges between $390,000 and $745,000. Actinium believes they can cut theses costs by reducing complications from BMT’s and diminishing inhouse days required for patients.
  • Approximately 22,000 patients received an autologous or allogeneic BMT’s in the United States in 2015.
  • This year, approximately 172,000 patients will be diagnosed with leukemia, lymphoma or multiple myeloma and that approximately 1.2 million patients are living with, or are in remission from these diseases.
  • Actinium believes the aggregate worldwide market potential for the treatment of AML, MDS, ALL, Hodgkin’s Lymphoma, NHL and multiple myeloma is approximately $6.6 billion.

Investment Potential

  • Actinium shares have shown a drastic decrease in value over the past 5 years:

ATNM stock.JPG

  • The stock’s value peaked in March, 2014 at $12.40 and has trended downward to its current price of $0.38.
  • The reduction in share price can be explained primarily by the longer than projected site activation times, education and coordination for Iomab-B.
  • Actinium is targeting the second half of 2019 for Iomab-B’s Biologics License Application to the FDA, which, if approved, would allow Actinium to commercialize their drug.
  • The potential approval would allow Actinium to infiltrate an emerging market and could reap tremendous financial gain for early investors.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s